X4 Pharmaceuticals Inc. (NASDAQ:XFOR)’s traded shares stood at 1.53 million during the last session, with the company’s beta value hitting 0.67. At the close of trading, the stock’s price was $0.84, to imply a decrease of -4.00% or -$0.04 in intraday trading. The XFOR share’s 52-week high remains $2.41, putting it -186.9% down since that peak but still an impressive 22.62% since price per share fell to its 52-week low of $0.65. The company has a valuation of $104.69M, with an average of 0.9 million shares in intraday trading volume over the past 10 days and average of 911.54K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for X4 Pharmaceuticals Inc. (XFOR), translating to a mean rating of 1.70. Of 8 analyst(s) looking at the stock, 0 analyst(s) give XFOR a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 8 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.24.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
X4 Pharmaceuticals Inc. (NASDAQ:XFOR) trade information
After registering a -4.00% downside in the last session, X4 Pharmaceuticals Inc. (XFOR) has traded red over the past five days. The stock hit a weekly high of 0.9500 this Friday, 03/17/23, dropping -4.00% in its intraday price action. The 5-day price performance for the stock is -5.11%, and -15.66% over 30 days. With these gigs, the year-to-date price performance is -15.41%. Short interest in X4 Pharmaceuticals Inc. (NASDAQ:XFOR) saw shorts transact 1.08 million shares and set a 1.27 days time to cover.
Analysts on Wall Street suggest a consensus price target of $4.50, implying an increase of 81.33% to the stock’s current value. The extremes give us $3.00 and $7.00 for target low and target high price respectively. As such, XFOR has been trading -733.33% off suggested target high and -257.14% from its likely low.
X4 Pharmaceuticals Inc. (XFOR) estimates and forecasts
Looking at statistics comparing X4 Pharmaceuticals Inc. share performance against respective industry, we note that the company has outperformed competitors. X4 Pharmaceuticals Inc. (XFOR) shares are -30.00% down over the last 6 months, with its year-to-date growth rate higher than industry average at 65.16% against 9.60%. Revenue is forecast to grow 80.60% this quarter before jumping 70.80% for the next one.
XFOR Dividends
X4 Pharmaceuticals Inc. has its next earnings report out on March 21. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. X4 Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
X4 Pharmaceuticals Inc. (NASDAQ:XFOR)’s Major holders
X4 Pharmaceuticals Inc. insiders hold 0.57% of total outstanding shares, with institutional holders owning 46.47% of the shares at 46.74% float percentage. In total, 46.47% institutions holds shares in the company, led by NEA Management Company, LLC. As of Sep 29, 2022, the company held over 6.52 million shares (or 9.42% of shares), all amounting to roughly $11.15 million.
The next major institution holding the largest number of shares is Bain Capital Life Sciences Investors, LLC with 6.39 million shares, or about 9.23% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $10.93 million.
We also have Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the X4 Pharmaceuticals Inc. (XFOR) shares. Going by data provided on Sep 29, 2022, Vanguard Total Stock Market Index Fund holds roughly 2.9 million shares. This is just over 4.19% of the total shares, with a market valuation of $4.96 million. Data from the same date shows that the other fund manager holds a little less at 0.31 million, or 0.44% of the shares, all valued at about 0.46 million.
